Shares of Eli Lilly and Co. tumbled 9.6% in premarket trading Wednesday, after the drug maker reported third-quarter profit and revenue that missed expectations by wide margins, as sales of obesity ...
The shortage of Eli Lilly’s (LLY) blockbuster diabetes and weight loss drugs is officially over, according to the U.S. Food and Drug Administration (FDA). The FDA updated its drug shortage ...
If you buy through links on this page, we may earn a small commission. Here’s our process. Zepbound (tirzepatide) is an injectable drug for weight loss in those with obesity or those with ...